ICRA upgrades long term rating on Patanjali Ayurved

Published On 2017-01-21 07:00 GMT   |   Update On 2017-01-21 07:00 GMT

New Delhi : Credit rating agency ICRA has upgraded long term rating on Baba Ramdev-led Patanjali Ayurved Ltd (PAL) to enhanced degree of adequate safety with stable outlook citing the company's "robust revenue growth in FY 2016" and increased brand penetration.


"ICRA has upgraded the long term rating of Patanjali Ayurved Ltd from A minus to A plus for Rs 300-crore fund based facilities. The outlook on the long-term rating is Stable," ICRA said.


It further said: "ICRA has also upgraded the short term rating of PAL from A two plus to A one for Rs 20 crore non fund based facilities."


Explaining the rationale of the rating upgrade, ICRA said it factored in PAL's robust revenue growth in FY2016 (Rs 4,812 crore from Rs 2,007 crore in FY2015) and the current fiscal (around Rs 3,600 crore in seven months), supported by increasing brand penetration through strengthened marketing in the recent past and strong following of Baba Ramdev among others.


Moreover, with continuous new product introduction, the Haridwar-based company has "one of the widest product portfolio amongst the FMCG players operating in India."


PAL has also strengthened its distribution network by adding both number as well as layers of intermediaries in order to support the business growth.


"These factors combined with partial backward integration and relatively lower selling and administrative overheads have enabled PAL to maintain its healthy profitability margins and return indicators, in spite of high competitive pressures," it said.


ICRA further added: "PAL's liquidity remains strong on the back of healthy internal accrual generation, sizeable cash balances and limited debt repayment liability resulting in moderate utilisation of the working capital limits availed from the bank. This coupled with a sizeable net worth has continued to result in low gearing levels and robust debt protection metrics."

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News